Co-delivery of doxorubicin and siRNA with reduction and pH dually sensitive nanocarrier for synergistic cancer therapy.
about
siRNA Delivery by Stimuli-Sensitive NanocarriersNanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatmentpH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery.Redox-sensitive nanoparticles from amphiphilic cholesterol-based block copolymers for enhanced tumor intracellular release of doxorubicin.Effective combination treatment of lung cancer cells by single vehicular delivery of siRNA and different anticancer drugs.Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.Drug and gene co-delivery systems for cancer treatment.Lipidoid nanoparticle mediated silencing of Mcl-1 induces apoptosis in mantle cell lymphoma.Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy.Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions.Superior intratumoral penetration of paclitaxel nanodots strengthens tumor restriction and metastasis prevention.Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy.Overcoming multiple drug resistance by spatial-temporal synchronization of epirubicin and pooled siRNAs.Redox-Triggered Gatekeeper-Enveloped Starlike Hollow Silica Nanoparticles for Intelligent Delivery Systems.Design of Block Copolymer Micellar Aggregates for Co-Delivery of Enzyme and Anticancer Prodrug.Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.Co-Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects.Recent advances in co-delivery systems based on polymeric nanoparticle for cancer treatment.Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance.Co-delivery of doxorubicin and arsenite with reduction and pH dual-sensitive vesicle for synergistic cancer therapy.Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer.Targeted Co-delivery of PTX and TR3 siRNA by PTP Peptide Modified Dendrimer for the Treatment of Pancreatic Cancer.Intelligent micellar polymeric nanocarriers for therapeutics and diagnosisStimuli-Regulated Smart Polymeric Systems for Gene TherapyTumor-targeted aggregation of pH-sensitive nanocarriers for enhanced retention and rapid intracellular drug release
P2860
Q26781212-7C38DA56-DB60-41AC-A3DA-BDE0DE964B69Q26866566-9C7ECD13-8D60-48F4-973C-C3E480489524Q36137279-C9C1FE81-97E7-419E-95B6-C5819CA40F9EQ36236817-AD3ED25A-12AC-4235-B14D-99497BBF931BQ37265705-D348B7BC-FC55-4D99-BDCB-858498932502Q38555082-7812A6BA-C6C3-441E-B07E-D8498EC46AB8Q38556764-5B195C4C-0BE6-499C-B8E8-6D3B32A29A26Q38782716-2FBBE382-486B-4C39-AA5F-2EED10FD0CE8Q38836010-3BA0146D-C85C-4F46-9574-C4CFC4DAB70CQ38881452-35F05754-FEE4-42FE-B526-9FE7E792549BQ38910127-8C849DDA-9FED-49BA-9668-01B951B25CDEQ41734074-1343DCD0-585D-400E-A92A-4EE5ACF1C75EQ45872645-486929D9-7CCE-4A82-A192-73FC8FC69E31Q45880403-2869AC27-8912-4440-996A-1ECEDC8C8A01Q46446276-B87F0074-40C7-45EB-AF6E-7AF5F248A1C9Q47378147-C1AFE6EA-EB55-4D54-8B29-07F6825F9C2FQ47642768-C8863109-380B-4038-A4C7-66349029AAC0Q49714833-2EEC43E6-AD8F-401D-BE08-A569B83BB8D7Q49788112-9E4DCB45-8FE1-4A9D-81D0-7C133152A2B3Q50895514-230DEB36-88DD-414E-BAED-1BAD307735B3Q50957929-2AD5CD87-BACC-4C03-BD43-FF77AEA9DF15Q51131993-BA8529D8-E1D0-45A7-A2CE-3DAC5D36D8DEQ57342189-6B8168D1-FD98-4D62-A691-42A21AF01199Q57372316-D313329E-AEB2-4DA3-8061-435CB85AE701Q59204669-4BA2EAEE-5C59-4FA8-B393-427149A9A96B
P2860
Co-delivery of doxorubicin and siRNA with reduction and pH dually sensitive nanocarrier for synergistic cancer therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Co-delivery of doxorubicin and ...... or synergistic cancer therapy.
@en
Co-delivery of doxorubicin and ...... or synergistic cancer therapy.
@nl
type
label
Co-delivery of doxorubicin and ...... or synergistic cancer therapy.
@en
Co-delivery of doxorubicin and ...... or synergistic cancer therapy.
@nl
prefLabel
Co-delivery of doxorubicin and ...... or synergistic cancer therapy.
@en
Co-delivery of doxorubicin and ...... or synergistic cancer therapy.
@nl
P2093
P2860
P356
P1433
P1476
Co-delivery of doxorubicin and ...... for synergistic cancer therapy
@en
P2093
Jifeng Chen
Weicai Chen
Yuanyuan Yuan
P2860
P304
P356
10.1002/SMLL.201303951
P577
2014-03-25T00:00:00Z